Recently, Capricor announced that it had initiated its rolling Biologics License Application (BLA) submission process with the U.S. FDA seeking full approval of deramiocel to treat all patients ...

You may also refer to our quarterly report on Form 10-Q which we expect to become available shortly and will be accessible on the SEC website as well as the financial section of Capricor's website.

The abstract will be made available on the publications section of the Capricor website.

Capricor presented preclinical data at the 2024 American Association of Extracellular Vesicles (AAEV) Annual Meeting ...

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated ... is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with ...

Capricor Therapeutics (NASDAQ:CAPR – Free Report) had its price objective raised by Cantor Fitzgerald from $25.00 to $30.00 ...

Capricor Therapeutics Inc (NASDAQ:CAPR – Free Report) – Stock analysts at HC Wainwright upped their FY2024 earnings per share ...

In this article, we are going to take a look at where Capricor Therapeutics, Inc. (NASDAQ:CAPR) stands against other best multibagger stocks. November has been an eventful month so far for the ...

(CAPR) is one of them. Here are the key reasons why this stock is a solid choice for "trend" investing. A solid price increase over a period of 12 weeks reflects investors' continued willingness ...

Is Capricor Therapeutics (CAPR) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this ...